Analgesics in Saudi Arabia has recorded robust value growth in 2026, due to a unique convergence of rapid digital healthcare integration, rising consumer demand for immediate pain relief, and a supportive regulatory and economic environment. With retail sales reaching SAR2,250 million and a year-on-year current value increase of 10%, analgesics remains a highly attractive environment, underpinned by entrenched self-medication habits, strong reliance on pharmacists and physicians, and significant investments by both local and international manufacturers. The surge in e-commerce, expansion of omnichannel pharmacy services, and the government’s Vision 2030 push for localised pharmaceutical production are reshaping the competitive dynamics and driving innovation, while the dominance of established brands such as Fevadol and continued growth in systemic and topical analgesics highlight both consumer trust and the appetite for specialised solutions. To succeed, brands should prioritise digital engagement, invest in portfolio diversification — particularly in targeted and locally produced pain relief products — and leverage trusted retail pharmacy channels to build loyalty and meet evolving consumer expectations in an increasingly digital-first environment.
Delivery:
Files are delivered directly into your account soon after payment is received and any tax is certification is verified (where applicable).
This report comes in PDF with additional info in Excel included.
Overview:
Understand the latest market trends and future growth opportunities for the Analgesics industry in Saudi Arabia with research from Euromonitor International's team of in-country analysts – experts by industry and geographic specialisation.
Key trends are clearly and succinctly summarised alongside the most current research data available. Understand and assess competitive threats and plan corporate strategy with our qualitative analysis, insight and confident growth projections.
If you're in the Analgesics industry in Saudi Arabia, our research will help you to make informed, intelligent decisions; to recognise and profit from opportunity, or to offer resilience amidst market uncertainty.
The Analgesics in Saudi Arabia report includes:
- Analysis of key supply-side and demand trends
- Detailed segmentation of international and local products
- Historic volume and value sizes, company and brand market shares
- Five year forecasts of market trends and market growth
- Robust and transparent research methodology, conducted in-country
This report answers:
- What is the market size of Analgesics in Saudi Arabia?
- Which are the leading brands in Analgesics in Saudi Arabia?
- How are products distributed in Analgesics in Saudi Arabia?
- How has the regulatory and operating environment for Analgesics changed in Saudi Arabia?
- How are considerations such as stress, self-medication and shifting consumer lifestyles shaping demand for Analgesics
- How significant are wider health concerns and consumer awareness in determining sales?
- Where is future growth expected to be most dynamic?
Key Data Insights
Nahdi and Wasfaty boost pharmacy footfall through digital integration
Systemic analgesics maintains its lead and drives growth, while digital solutions expand
Bayer’s local manufacturing of Aspirin Protect drives prevention focus
Chart 1 Value Sales 2021-2031
Chart 2 Value Sales by Category 2026
Online pharmacy platforms will expand access as consumer habits shift
Systemic analgesics set to remain the main growth driver
Vision 2030 expected to drive digital innovation and local supply resilience
Chart 1 Forecast Value Sales 2021-2031
Chart 2 Forecast Value Sales by Category 2026-2031
Spimaco and its Fevadol brand reinforce leadership as innovation drives competition
Product development impacts the competitive landscape
Chart 1 Company Shares 2026
Chart 2 Brand Shares 2026
Pharmacies sustains dominance, with digital and omnichannel integration seen
Quick commerce platforms emerge as new digital competitors
Chart 1 Retail Channels 2021-2026
Chart 1 Real GDP Growth 2021-2031
Chart 2 Inflation 2021-2031
Chart 1 Population 2021-2031
Chart 2 Population by Generation 2026
Chart 3 Consumer Expenditure 2021-2031
Country Reports Disclaimer
The following categories and subcategories are included:
Analgesics
-
-
- Adult Acetaminophen
- Adult Aspirin
- Adult Combination Products - Analgesics
- Adult Diclofenac
- Adult Dipyrone
- Adult Ibuprofen
- Adult Ketoprofen
- Adult Naproxen
- Adult OTC Triptans
-
- Paediatric Acetaminophen
- Paediatric Aspirin
- Paediatric Combination Products - Analgesics
- Paediatric Dipyrone
- Paediatric Ibuprofen
- Paediatric Naproxen
-
- Acetaminophen
- Aspirin
- Combination Products - Analgesics
- Diclofenac
- Dipyrone
- Ibuprofen
- Ketoprofen
- Naproxen
- OTC Triptans
-
- Topical Analgesics/Anaesthetic
Analgesics
Analgesics cover systemic and topical pain relievers. Products which include a pain-relief ingredient in addition to another core function are excluded (e.g. a sore throat remedy which includes paracetamol is excluded from the analgesics and instead is included in pharyngeal remedies).
See all of our definitionsWhy buy this report?
- Gain competitive intelligence about market leaders
- Track key industry trends, opportunities and threats
- Inform your marketing, brand, strategy and market development, sales and supply functions
This report originates from Passport, our Analgesics research and analysis database.
NEW REPORT GUARANTEE
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extraction Free!